Mirna enrolled the first patient in hematologic malignancies MRX34 cohort Phase 1 clinical trial -
Mirna Therapeutics, Inc. (Mirna), a biopharmaceutical company in clinical stage replacement pioneer basic microRNA therapy to treat cancer, announced today recruitment of the first patient in hematologic malignancy cohort of its Phase 1 clinical trial being MRX34, lead product candidate of the company and the first microRNA mimic in human clinical trials in oncology.
"We believe that the therapy very promising microRNAs in the fight against cancer and we're excited to extend the ongoing clinical study of MRX34 in liver-based cancers, to now include patients with hematologic cancers, "said Jorge Cortes, MD, Vice President Department, Department of leukemia, Division of cancer medicine at MD Anderson cancer Center and principal investigator of the study.
study multicentre, open-label phase 1 clinical trial MRX34 was launched in April 2013 and is currently enrolling patients with hepatocellular carcinoma unresectable or solid cancers liver with liver damage. the trial is now recruiting a separate cohort of tumor patients hematologic malignancies, are cancers that affect blood nodes, bone marrow and lymph nodes and may include non-Hodgkin's lymphoma, acute myeloid leukemia, acute and chronic lymphocytic leukemia, accelerated chronic myeloid leukemia or blast phase, the multiple myeloma or myelodysplastic syndrome.
An interim analysis of safety data from the first 26 patients were recently presented at the American Association of Clinical Research (AACR) annual meeting. Preliminary data showed that the most common side effects associated with MRX34 in the patients studied were manageable with standard procedures used by oncologists with an incident of dose limiting toxicity observed. The maximum tolerated dose was not reached and additional patients are being enrolled in the study.
EmoticonEmoticon